Bebifrin, drops 0.125% 10 ml

An anticonvulsant agent – alpha-adrenomimetic.

ATX code: R01AA04 Pharmacological properties

Pharmacodynamics

The drug for symptomatic local treatment of rhinitis. Phenylephrine hydrochloride is an agonist of alpha 1-adrenergic receptors (sympathomimetics) which produces vasoconstrictor effect due to stimulation of alpha1-receptors in the nasal mucosa, it reduces mucous membrane swelling and hyperemia of tissues, congestion in the nasal mucosa and improves nasal airway patency.

The restoration of nasopharyngeal airflow makes the patient feel better and reduces the risk of possible complications from mucociliary congestion.

Pharmacokinetics

In topical administration, systemic absorption is low.

Indications

Active ingredient

Composition

1 ml of the drug contains:

The active ingredient:

Phenylephrine hydrochloride 1.25 mg

Excipients:

Benzalkonium chloride 0.18 mg

Glycerol anhydrous 50.00 mg

Macrogol 1500 (polyethylene glycol 1500) 15.00 mg

Sodium hydrophosphate dihydrate 2.26 mg

Potassium dihydrophosphate 1.01mg

Dinatrium edetate dihydrate (trilon B) 0.20 mg

Injection water to 1 ml.

How to take, the dosage

Interaction

Special Instructions

In children systemic absorption of phenylephrine and the associated risk of side effects is higher than in adults.
The duration of use of the drug should not exceed 3 days, if nasal breathing difficulties persist, further use of the drug should be agreed with the doctor.

Phenylephrine should not be administered to patients within 2 weeks after withdrawal of MAOI inhibitors because it may increase the severity of adrenergic effects of sympathomimetic agents and increase the risk of cardiovascular side effects.
It is not recommended to use the same vial in several persons to avoid spread of infection.

There are no data on the negative effect of the drug on the ability to drive a car and other vehicles. However, when symptoms of side effects of the drug are observed, one should refrain from driving vehicles and performing activities requiring concentration and quick psychomotor reactions.

Contraindications

Individual hypersensitivity to the components of the drug; cardiovascular diseases (including significant atherosclerosis, angina pectoris, tachycardia), thyroid disease (thyrotoxicosis), diabetes mellitus, arterial hypertension, simultaneous use of monoamine oxidase (MAO) inhibitors (and 2 weeks after their withdrawal), children under 4 years old.

Children under 6 years of age; pheochromocytoma; with hypersensitivity to adrenergic agents, accompanied by sleep disturbances, dizziness, skeletal muscle tremors, arrhythmias, increased blood pressure.

Side effects

Overdose

Pregnancy use

Similarities